Filing Flows › Cryo Cell International (CCEL) › How it makes money
How Cryo Cell International (CCEL) makes money
Cryo Cell International (CCEL) made $7.8M of revenue in the third quarter fiscal 2026 (Q3 FY26), 0% from a year earlier. Processing and Storage Fees brought in $7.7M (98%); Public Banking brought in $135K (2%); Product brought in $39K (0%). Of every dollar of revenue, 28¢ was left as operating profit, 16¢ was left as net earnings.
Drawing the Sankey…
Revenue by segment, Q3 FY26
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Processing and Storage Fees | $7.7M | 97.8% | -0.8% | -2% |
| Public Banking | $135K | 1.7% | +190% | 33× |
| Product | $39K | 0.5% | +174% | 89× |
Where each dollar of revenue goes
| Line | Q3 FY26 | % of revenue |
|---|---|---|
| Revenue | $7.8M | 100.0% |
| Operating profit | $2.2M | 28.0% |
| Income tax | $555K | 7.1% |
| Net earnings | $1.3M | 16.2% |
| Operating cash flow | $1.1M | 14.6% |
| Free cash flow | $1.0M | 13.3% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 FY26 | $7.8M | 0% |
| Q2 FY26 | $7.8M | -2% |
| Q1 FY26 | $7.7M | -4% |
| Q4 FY25 | $7.8M | -2% |
| Q3 FY25 | $7.8M | -3% |
| Q2 FY25 | $7.9M | -1% |
| Q1 FY25 | $8.0M | +2% |
From Cryo Cell International's 10-Q filed Oct 9, 2026 (on EDGAR).
Questions
How does Cryo Cell International make money?
Cryo Cell International (CCEL) made $7.8M of revenue in the third quarter fiscal 2026 (Q3 FY26), 0% from a year earlier. Processing and Storage Fees brought in $7.7M (98%); Public Banking brought in $135K (2%); Product brought in $39K (0%). Of every dollar of revenue, 28¢ was left as operating profit, 16¢ was left as net earnings.
What is Cryo Cell International's biggest business?
Processing and Storage Fees: $7.7M in the third quarter fiscal 2026, 98% of revenue, -2% from a year earlier.
What is Cryo Cell International's profit margin?
Net earnings were $1.3M, 16.2% of revenue, in the third quarter fiscal 2026; the operating margin was 28.0%.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.